Improving reporting of infection events in clinical trials.
作者信息
Ludwig Heinz, Munshi Nikhil C, Terpos Evangelos, Raje Noopur, Moreau Philippe, Nooka Ajay
机构信息
Wilhelminen Cancer Research Institute, Department of Medicine I, Clinic Ottakring, Vienna, Austria.
Dana-Farber Cancer Institute and Boston VA Healthcare System, Boston, MA.
出版信息
Blood Adv. 2024 Nov 26;8(22):5927-5928. doi: 10.1182/bloodadvances.2024014102.
Abstract
摘要
相似文献
1
Improving reporting of infection events in clinical trials.
Blood Adv. 2024 Nov 26;8(22):5927-5928. doi: 10.1182/bloodadvances.2024014102.
2
Quality of reporting of adverse events in clinical trials of covid-19 drugs: systematic review.
BMJ Med. 2023 Sep 21;2(1):e000352. doi: 10.1136/bmjmed-2022-000352. eCollection 2023.
3
Improving the capture and reporting of adverse events in clinical trials of non-pharmacological interventions: learnings from the PaCCSC/CST membership.
Trials. 2025 Mar 18;26(1):95. doi: 10.1186/s13063-025-08801-1.
4
Evolution of Hematology Clinical Trial Adverse Event Reporting to Improve Care Delivery.
Curr Hematol Malig Rep. 2021 Apr;16(2):126-131. doi: 10.1007/s11899-021-00627-3. Epub 2021 Mar 30.
5
Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in polycystic ovary syndrome.
Cochrane Database Syst Rev. 2020 Aug 13;8(8):CD005552. doi: 10.1002/14651858.CD005552.pub3.
6
The reporting of adverse events following spinal manipulation in randomized clinical trials-a systematic review.
Spine J. 2016 Sep;16(9):1143-51. doi: 10.1016/j.spinee.2016.05.018. Epub 2016 May 27.
7
Opportunities for selective reporting of harms in randomized clinical trials: Selection criteria for non-systematic adverse events.
Trials. 2019 Sep 5;20(1):553. doi: 10.1186/s13063-019-3581-3.
8
Online monitoring of patient self-reported adverse events in early phase clinical trials: Views from patients, clinicians, and trial staff.
Clin Trials. 2021 Apr;18(2):168-179. doi: 10.1177/1740774520972125. Epub 2020 Nov 24.
9
Improving adverse drug event reporting by healthcare professionals.
Cochrane Database Syst Rev. 2024 Oct 29;10(10):CD012594. doi: 10.1002/14651858.CD012594.pub2.
10
Ivermectin for preventing and treating COVID-19.
Cochrane Database Syst Rev. 2022 Jun 21;6(6):CD015017. doi: 10.1002/14651858.CD015017.pub3.
引用本文的文献
1
Novelties on Multiple Myeloma from the Main 2024 Hematology Conferences.
Mediterr J Hematol Infect Dis. 2025 Mar 1;17(1):e2025027. doi: 10.4084/MJHID.2025.027. eCollection 2025.
本文引用的文献
1
Improving infection reporting in hematology treatment trials.
Blood Adv. 2024 Nov 26;8(22):5925-5926. doi: 10.1182/bloodadvances.2024013859.
2
Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis.
Blood Adv. 2023 Jul 11;7(13):3069-3074. doi: 10.1182/bloodadvances.2022009435.
3
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
Leukemia. 2020 Apr;34(4):985-1005. doi: 10.1038/s41375-020-0734-z. Epub 2020 Feb 13.
Zotero 插件